| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
IDEAYA Biosciences, Inc.$36.99
-0.29 (-0.78%)
C 52Pipeline Score Overvalued Pharma · Commercial
Market Cap
2.56 B
EPS
-1.58
P/E Ratio
-
Value Trade
30.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.56 M
R&D Expenses
95.73 M
Operating CF
-75.17 M
Total Assets
1.03 B
Total Liabilities
93.08 M
Equity
937.27 M
D/E Ratio
12,345
1.78 %
Week
-8.58 %
1 Month
-11.55 %
3 Month
-12.4 %
6 Month
43 %
5 Year
107.86 %
All Time
Cash Data
Cash Position
671.20 M
Monthly Burn
25.06 M
Runway
24.8 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
677.50 K
52 Week Range
18.77 - 39.28
% held by Insiders
5.45 %
% held by Institutions
96.59 %
Enterprise Value
1.91 B
Total Shares
87.87 M
Short %
11.87 %
Float Shares
87.08 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IDEAYA Biosciences, Inc.
362Total events
4Upcoming
69Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 4
Event history 358
Q3 2026
◆Enrollment MilestoneIDE892Trial
IDE892 monotherapy expansion anticipated in Q3 2026
MTAP-deleted solid tumorssource ↗
Jun 15, 2026
▲First Patient DosedIDE892Trial
First patient enrolled in Phase 1 combination trial of IDE892 + IDE397 in MTAP-deleted solid tumors
MTAP-deleted solid tumors (NSCLC, pancreatic cancer)source ↗
Jun 10, 2026
▼Equity OfferingCorporate
Closing of underwritten public offering of common stock and pre-funded warrants, including full exercise of underwriters' option, raising approximately $345.0 million in gross proceeds
Jun 8, 2026
▼Equity OfferingCorporate
Proposed public offering of common stock and pre-funded warrants up to $300 million
Jun 3, 2026
▲Partnership / LicenseCorporate
Clinical collaboration with Roche to evaluate IDE892 + RG6505 in MTAP-deleted RAS-mutant PDAC
Jun 3, 2026
▲Trial InitiationIDE892Trial
Phase 1 dose escalation trial of IDE892 in MTAP-deleted solid tumors ongoing
MTAP-deleted solid tumorssource ↗
Jun 1, 2026
▲Late-BreakerDarovasertibPresentation
Late-breaking oral presentation of complete data from primary analysis of OptimUM-02 at ASCO 2026
first line HLA*A2:01 negative metastatic uveal melanomasource ↗
Jun 1, 2026
▲Topline ReadoutDarovasertibClinical Data
Primary PFS results from OptimUM-02 trial: darovasertib + crizotinib vs investigator's choice in first-line HLA-A2 negative metastatic uveal melanoma
HLA-A2 negative metastatic uveal melanomasource ↗
Jun 1, 2026
▲Primary Endpoint MetDarovasertibClinical Data
Primary endpoint PFS met with statistical significance
HLA-A2 negative metastatic uveal melanomasource ↗
Jun 1, 2026
◆Full ResultsDarovasertibClinical Data
Primary results from OptimUM-02 presented at medical conference
HLA-A2 negative metastatic uveal melanomasource ↗
Jun 1, 2026
◆Oral PresentationDarovasertibPresentation
Oral presentation of OptimUM-02 primary results
HLA-A2 negative metastatic uveal melanomasource ↗
Drug Pipeline Intelligence
C52
Pipeline Score $768M
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.3x
rNPV / MCap Top 79%
Small Cap (rank 192 of 911)
Percentile RankIDEAYA Biosciences, Inc. carries a moderate pipeline score (52/100), with $1.2B risk-adjusted pipeline value, led by IDE-161 in Advanced or Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDE-161 Small molecule | Advanced or Metastatic Solid Tumors | Phase 1 | NCT05787587 | 5% | $941M | ACTIVE NOT_RECRUITING | 216 | FAST | C (46) | May 1, 2027 | MODERATE_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
darovasertib Breakthrough | HLA*A2:01 negative metastatic uveal melanoma | Phase 2/3 | 2026-06-02 | 313 patients, significant improvements in response rates and progression-free survival Read More | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO Read More | |
darovasertib Breakthrough | HLA*A2:01 negative metastatic uveal melanoma | Phase 2/3 | 2026-06-02 | 313 patients, significant improvements in response rates and progression-free survival Read More | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO Read More | |
darovasertib Breakthrough | HLA*A2:01 negative metastatic uveal melanoma | Phase 2/3 | 2026-06-02 | 313 patients, significant improvements in response rates and progression-free survival Read More | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IDYA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IDYA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IDYAIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
IDEAYA Biosciences has elected Yujiro S. Hata as Chairman of the Board. Hata, who is also the President and CEO, has been instrumental in the company's evolution into a leading precision medicine oncology firm. The company is focused on developing breakthrough therapies for cancer, addressing significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a promising PRMT5 inhibitor, in combination with IDE397 for treating MTAP-deleted pancreatic and lung cancers. The trial aims to address the significant unmet need for effective therapies in these cancer types, where MTAP deletion is prevalent. Preclinical results indicate strong anti-tumor activity, supporting the rationale for this combination therapy.
Read more →IDYAIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Biosciences has successfully closed its public offering of 7,222,225 shares at $27.00 each, raising approximately $345 million. The offering included a full exercise of the underwriters' option for an additional 1,666,669 shares. The company aims to advance its precision medicine oncology initiatives with these funds.
Read more →IDYA▼ -10.8%on this newsshared move
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $300 million. The offering includes 5,555,556 shares of common stock priced at $27.00 each and pre-funded warrants at $26.9999. The transaction is expected to close around June 10, 2026, subject to customary conditions.
Read more →IDYA▲ +11.3%on this newsshared move
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
IDEAYA Biosciences announced a proposed public offering of up to $300 million in common stock and pre-funded warrants. The offering is subject to market conditions, and underwriters have a 30-day option to purchase an additional $45 million. The company aims to leverage this capital for its precision oncology initiatives.
Read more →IDYAIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA Biosciences has announced a clinical collaboration with Roche to evaluate the efficacy of IDE892, a PRMT5 inhibitor, in combination with Roche's RG6505 for treating MTAP-deleted RAS-mutant pancreatic cancer. The trial aims to address the high unmet need in this patient population. Both companies will retain commercial rights to their respective compounds.
Read more →IDYAIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
IDEAYA Biosciences and Servier presented complete data from the Phase 2/3 OptimUM-02 trial at ASCO 2026, showcasing the darovasertib combination's effectiveness in treating HLA*A2:01 negative metastatic uveal melanoma. The trial demonstrated significant improvements in response rates and progression-free survival compared to existing therapies. The FDA is reviewing the NDA for this combination under the Real-time Oncology Review program, which may expedite approval.
Read more →IDYAIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of...
IDEAYA Biosciences and Servier presented data from the Phase 2/3 OptimUM-02 trial at ASCO 2026, showing that the darovasertib combination significantly improved median progression-free survival (PFS) in HLA*A2:01 negative metastatic uveal melanoma patients. The trial demonstrated a 58% reduction in disease progression risk and a promising overall response rate. The NDA submission is underway under the FDA's RTOR program, aiming for potential accelerated approval.
Read more →IDYAHLA, human leukocyte antigen. mOS, median overall survival. mPFS, median progression free survival. PKC, protein kinase C. 1. Khoja L, et al. J Clin Oncol. 2025;43(suppl) [abstract 9539]. 2. Rantala ES, et al. Melanoma R
The OptimUM-02 trial evaluated the first-line treatment of darovasertib plus crizotinib for patients with HLA-A*02:01 negative metastatic uveal melanoma. Results indicated a significant improvement in progression-free survival (PFS) compared to standard treatments, demonstrating a 58% reduction in the risk of disease progression or death. The combination therapy presents a potential new option for a patient population with historically limited treatment choices, given the absence of FDA-approved therapies for this subgroup.
Read more →IDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 c 4
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635 c 4
Read more →IDYAIDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
IDEAYA Biosciences announced its participation in the 2026 Jefferies Global Healthcare Conference. The company will host a fireside chat and an AI panel discussion featuring its CEO, Yujiro S. Hata. Live webcasts of the events will be available, along with a replay for 30 days post-event. IDEAYA focuses on precision medicine for oncology.
Read more →IDYAIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences reported positive topline results from its OptimUM-02 trial, paving the way for its first NDA submission for accelerated approval. The company anticipates a catalyst-rich second half of 2026 with updates on several clinical programs. However, it also reported a net loss increase and a decrease in cash reserves compared to the previous quarter.
Read more →IDYAIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences announced that the FDA will review its NDA for darovasertib in combination with crizotinib for patients with HLA*A2-negative metastatic uveal melanoma. The decision follows positive topline results from the OptimUM-02 trial, which showed a 58% reduction in disease progression risk. IDEAYA plans to initiate the RTOR submission process in May 2026.
Read more →IDYA▼ -5.3%on this news
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences announced a late-breaking abstract oral presentation at ASCO 2026, focusing on the OptimUM-02 trial of darovasertib combined with crizotinib for HLA*A2-negative metastatic uveal melanoma. The presentation will reveal complete data not previously disclosed. Dr. Marlana Orloff will present the findings on June 1, 2026.
Read more →IDYA▲ +7.6%on this news
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences and Servier announced positive topline results from their Phase 2/3 trial, OptimUM-02, for darovasertib combined with crizotinib in treating first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination showed a statistically significant improvement in median progression-free survival compared to the investigator choice of therapy. The study provides promising data for a new treatment option in a patient population with high unmet medical need.
Read more →IDYAIDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
IDEAYA Biosciences plans to announce topline results from its Phase 2/3 OptimUM-02 trial on April 13, 2026. The trial evaluates darovasertib combined with crizotinib for treating first-line HLA*A2-negative metastatic uveal melanoma. A conference call and webcast will provide insights from IDEAYA's management and a key opinion leader.
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target...
IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 trial for IDE574, a dual inhibitor targeting KAT6 and KAT7. This potential first-in-class therapy aims to address multiple solid tumor types, including breast and prostate cancers. The drug has shown promising preclinical efficacy, outperforming selective inhibitors in tumor models.
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
IDEAYA Biosciences has announced the enrollment of the first patient in a Phase 1 clinical trial evaluating the combination of IDE849 and IDE161 for DLL3 upregulated solid tumors. The trial aims to assess the safety and efficacy of this first-in-class combination in treating conditions such as small cell lung cancer and melanoma. Preliminary data indicates promising results, with multiple partial responses observed in patients.
Read more →IDYA▼ -5.1%on this newsshared move
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences announced the granting of non-qualified stock options to two new employees as part of its 2023 Employment Inducement Incentive Award Plan. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to the company. The stock options have a 10-year term and will vest over four years, contingent on continued employment.
Read more →IDYAIDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
IDEAYA Biosciences announced its participation in investor relations events and provided updated guidance on the topline results from the Phase 2/3 OptimUM-02 trial for darovasertib. The events will take place on May 12 and May 19, 2026, with webcasts available for investors. The company emphasizes its commitment to precision oncology and the development of targeted therapies.
Read more →IDYAIDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster ...
IDEAYA Biosciences has announced three poster presentations at the AACR Annual Meeting, showcasing data from its clinical stage pipeline. The programs include IDE034, IDE574, and IDE892, which target various cancer mechanisms. These presentations aim to highlight the company's commitment to developing innovative therapies for solid tumors.
Read more →IDYAIDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
Read more →IDYA▲ +5.7%on this news
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Read more →IDYA▲ +5.7%on this news
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update Potential best-in-class profile, including ~1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes, and single-digit nanomolar potency...
IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 trial for IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors. The trial will evaluate IDE892 as a monotherapy and in combination with IDE397. The company also plans to advance its CDKN2A-deficiency program, aiming for a development candidate by late 2026.
Read more →IDYABiocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals announced the first patient dosing in IDEAYA's Phase 1 trial of IDE034, a bispecific ADC targeting B7H3/PTK7. This milestone triggers a $5 million payment to Biocytogen. The trial aims to evaluate IDE034's safety and tolerability, with potential combination therapies planned. IDE034 is designed to selectively target tumor cells, indicating promising therapeutic potential.
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
IDEAYA Biosciences has announced the enrollment of the first patient in its Phase 1 trial for IDE034, a bispecific TOP1 antibody-drug conjugate targeting B7H3 and PTK7. The trial will assess the safety and tolerability of IDE034 as a monotherapy and in combination with IDE161, a proprietary PARG inhibitor. This milestone triggers a $5 million payment to Biocytogen, highlighting the significance of IDE034 in IDEAYA's oncology portfolio.
Read more →IDYAIDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDEAYA Biosciences has appointed Dr. Theodora Ross as Chief Development Officer, a newly created role. Dr. Ross will lead early clinical development for the company's oncology pipeline. She brings over 30 years of experience, previously serving at AbbVie. The leadership is optimistic about her impact on the company's growth and clinical strategies.
Read more →IDYAIDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences reported a strong fourth quarter and full year 2025, highlighting successful clinical execution and pipeline expansion. The company completed enrollment in its key clinical trial, OptimUM-02, and submitted IND filings for two promising drug candidates. Financially, IDEAYA ended the year with approximately $1.05 billion in cash, despite a net loss of $113.7 million.
Read more →IDYAIDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update 130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative...
IDEAYA Biosciences reported its fourth quarter and full year 2025 financial results, highlighting the completion of patient enrollment in the OptimUM-02 trial for darovasertib and crizotinib in metastatic uveal melanoma. The company anticipates topline results by March 2026 and plans to initiate multiple Phase 3 trials. IDEAYA's financial position remains strong with over $1 billion in cash, expected to support operations through 2030.
Read more →IDYA▲ +5.8%on this news
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences announced its participation in two upcoming investor relations events in February 2026. The events include Citi's Virtual Oncology Leadership Summit and a Virtual Fireside Chat hosted by Evercore ISI. Live audio webcasts will be available, with replays accessible for 30 days post-event. IDEAYA aims to advance precision oncology therapies.
Read more →IDYACertain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the "
IDEAYA Biosciences, Inc. provided forward-looking statements regarding its future financial performance and clinical programs during a recent healthcare conference. These statements highlight the company's ambitions in developing precision medicines, specifically in oncology. However, they also acknowledge the inherent risks associated with drug development and the uncertainties surrounding clinical trials, regulatory approvals, and market dynamics. Investors are advised that success relies on multiple assumptions that may evolve over time.
Read more →IDYAIDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key...
IDEAYA Biosciences provided a business update at the J.P. Morgan Healthcare Conference, outlining its corporate objectives for 2026. The company plans to advance four registrational trials for darovasertib, targeting uveal melanoma and other cancers. With a robust pipeline and significant cash reserves, IDEAYA aims to address high unmet medical needs in oncology.
Read more →IDYAIDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J P Morgan Healthcare Conference
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J P Morgan Healthcare Conference
Read more →IDYAIDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2026. The event will feature a live audio webcast of the presentation and Q&A session, which will be accessible for 30 days after the event. IDEAYA focuses on precision medicine and aims to develop targeted therapies for cancer.
Read more →IDYAIDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences has completed enrollment of 435 patients in its Phase 2/3 trial (OptimUM-02) for darovasertib combined with crizotinib in treating HLA*A2-negative metastatic uveal melanoma. The company anticipates reporting median progression-free survival data in Q1 2026, which may support an accelerated approval filing. The trial aims to address the significant unmet need in this aggressive cancer type.
Read more →IDYAIDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences has submitted an IND application for IDE574, a dual inhibitor targeting KAT6 and KAT7, with plans to initiate a Phase 1 trial in early 2026. The drug aims to disrupt tumor lineage identity and has shown promising anti-tumor activity in preclinical models. The company plans to present further data at a medical conference in 2026.
Read more →IDYAIDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences has received IND clearance from the FDA for IDE034, a bispecific ADC targeting solid tumors expressing B7H3 and PTK7. The Phase 1 trial is set to begin in Q1 2026, focusing on various cancers. Preclinical studies show promising anti-tumor activity, supporting its potential as a first-in-class therapy.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences will participate in two investor relations events in December 2025. The company is set to present at Citi's 2025 Global Healthcare Conference on December 2 and the 8th Annual Evercore Healthcare Conference on December 3. A live audio webcast will be available for both events, with replays accessible for 30 days.
Read more →IDYAIDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences reported strong financial results for Q3 2025, highlighting a net income of $119.2 million and a significant increase in collaboration revenue due to a partnership with Servier. The company continues to advance its pipeline, including multiple clinical data updates presented at major medical conferences. IDEAYA's cash reserves have also grown, supporting its ongoing operations and development efforts.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) September 30
IDEAYA Biosciences has released their third quarter financial results for 2025, highlighting significant progress in several clinical trials and partnership developments. Notably, they reported promising data from their darovasertib trials for metastatic uveal melanoma, with plans for accelerated approval in the U.S. Additionally, they secured a licensing agreement with Servier that extends their capabilities into 2030. The company also maintains a strong cash position to support ongoing operations and development.
Read more →IDYA▲ +10.9%on this news
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in two upcoming investor relations events in November 2025. The events include a fireside chat at Citi's SMID Cap Biopharma Call Series and the Jefferies Global Healthcare Conference in London. These engagements will feature CEO Yujiro S. Hata and will be accessible via live webcasts.
Read more →IDYA▲ +10.9%on this news
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences presented positive Phase 2 data for darovasertib in the neoadjuvant treatment of primary uveal melanoma at ESMO 2025. The trial showed significant tumor shrinkage and reduced risk of vision loss. This therapy addresses a critical unmet need, as there are currently no approved systemic treatments for this condition. The company is also advancing a Phase 3 trial and aims for accelerated approval in the U.S.
Read more →IDYAIDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences has announced positive median overall survival results from its Phase 1/2 trial of darovasertib combined with crizotinib for first-line treatment of metastatic uveal melanoma. The trial showed a median overall survival of 21.1 months and a disease control rate of 90%. The data will be presented at the 2025 Society for Melanoma Research Congress in Amsterdam. The company is also advancing a registration-enabling Phase 2/3 trial, OptimUM-02, targeting accelerated approval.
Read more →IDYA▼ -13.9%on this news
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
IDEAYA Biosciences announced positive initial data from its Phase 1/2 trial of IDE397 combined with Trodelvy for treating MTAP-deletion urothelial cancer. The trial included 19 patients, with a notable 68% having progressed after multiple therapies. The results indicate a promising early response rate, paving the way for further testing in non-small cell lung cancer.
Read more →IDYA▼ -13.9%on this newsshared move
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
Read more →IDYA▼ -13.9%on this newsshared move
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present positive interim data at their 10-Year...
IDEAYA Biosciences announced positive interim results from its Phase 2 OptimUM-09 trial of darovasertib for primary uveal melanoma. The treatment showed significant tumor shrinkage and reduced radiation exposure, leading to improved vision outcomes. The safety profile was manageable, with most adverse events being mild. The company plans to present further data at upcoming events.
Read more →IDYA▼ -13.9%on this newsshared move
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
IDEAYA Biosciences and Hengrui Pharma presented positive Phase 1 data for IDE849, a DLL3-targeting ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial involved 100 patients, showing an overall response rate of 73.2% in evaluable small cell lung cancer patients. The companies plan to advance IDE849's development for various cancers, addressing significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with...
IDEAYA Biosciences has enrolled its first patient in a Phase 1/2 trial combining IDE397, a MAT2A inhibitor, with Trodelvy for treating MTAP-deletion non-small cell lung cancer (NSCLC). This trial expands on previous research in MTAP-deletion urothelial cancer, aiming to address a significant gap in treatment options. The collaboration with Gilead is expected to enhance the development of this novel therapy.
Read more →IDYAIDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an investigational new drug (IND) ...
IDEAYA Biosciences has submitted an IND application for IDE892, a PRMT5 inhibitor targeting MTAP-deleted lung cancer. The company plans to initiate a Phase 1 trial in Q4 2025, with combination studies using IDE397 expected in early 2026. This development highlights IDEAYA's commitment to precision oncology and addressing significant treatment gaps.
Read more →IDYAServier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Read more →IDYAServier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US...
Servier and IDEAYA Biosciences have entered an exclusive license agreement for darovasertib, a treatment for uveal melanoma, granting Servier rights outside the US. IDEAYA will receive $210 million upfront, with additional milestone payments and royalties. The collaboration aims to accelerate darovasertib's development through three Phase 3 trials, addressing a significant unmet medical need in uveal melanoma.
Read more →IDYAIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Read more →IDYAIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's ...
IDEAYA Biosciences announced that an abstract detailing the first median overall survival data from its Phase 1/2 trial of darovasertib combined with crizotinib in metastatic uveal melanoma has been accepted for oral presentation at the 2025 Society for Melanoma Research Congress. This presentation will showcase data from over 40 patients, marking a significant advancement in treatment options for this cancer type.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in several investor relations events in September 2025. The events include the Cantor Global Healthcare Conference, IDEAYA's 10-Year Anniversary R&D Day, and the Morgan Stanley Global Healthcare Conference. These gatherings will feature key presentations and discussions on the company's pipeline and strategic direction.
Read more →IDYAIDEAYA Biosciences Announces Agenda for 10 Year Anniversary R D Day on September 8, 2025
IDEAYA Biosciences Announces Agenda for 10 Year Anniversary R D Day on September 8, 2025
Read more →IDYAIDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced its agenda for an R&D Day coinciding with its 10-year anniversary, scheduled for September 8, 2025. The event will highlight new clinical data on darovasertib and other therapies, as well as the company's future growth strategy. Dr. Arun D. Singh will present findings from the Phase 2 trial of darovasertib, and a live Q&A session will follow.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) June 30
IDEAYA Biosciences, Inc. reported positive financial results for Q2 2025, with several key clinical milestones on the horizon. The company is on track to present median progression-free survival data for the darovasertib and crizotinib combination in metastatic uveal melanoma by year-end 2025, which could facilitate a U.S. accelerated approval. Additionally, clinical updates from various trials are set to be showcased at major medical conferences. IDEAYA also announced a robust financial position with around $992 million in cash, expected to fund operations until 2029.
Read more →IDYAIDEAYA Biosciences, Inc Reports Second Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Second Quarter 2025 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS...
IDEAYA Biosciences reported its financial results for Q2 2025, highlighting a positive outlook with ongoing clinical trials for darovasertib and crizotinib in metastatic uveal melanoma. The company anticipates median progression-free survival data by year-end 2025, which could enable an accelerated approval filing. IDEAYA also plans to host its 10-year Anniversary R&D Day to present multiple clinical updates.
Read more →IDYA▲ +5.1%on this news
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
Read more →IDYA▲ +5.1%on this news
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that results from a multi-site global Phase 2 ...
IDEAYA Biosciences announced that results from a Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025. The study involved over 90 patients and aims to demonstrate the drug's effectiveness in preventing enucleation. The company has also initiated a Phase 3 trial to further explore darovasertib's potential.
Read more →IDYA▲ +7.3%on this newsshared move
IDEAYA Biosciences Announces 10 Year Anniversary R D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
IDEAYA Biosciences Announces 10 Year Anniversary R D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
Read more →IDYA▲ +7.3%on this newsshared move
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will host an R&D Day on September 8, 2025, to celebrate its 10-year anniversary. The event will feature multiple clinical data updates and outline the company's future growth strategy. Key members of the leadership team will present, emphasizing IDEAYA's commitment to precision medicine in oncology.
Read more →IDYAIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
Read more →IDYAIDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a...
IDEAYA Biosciences and Hengrui Pharmaceuticals announced an oral presentation at the IASLC 2025 World Conference on Lung Cancer. The presentation will showcase clinical efficacy and safety data from a Phase 1 trial of IDE849 in small-cell lung cancer patients. This potential first-in-class DLL3-TOP1 antibody drug conjugate aims to address significant unmet medical needs.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29, 2025. CEO Yujiro S. Hata will engage in a fireside chat hosted by Justin Zelin. A live audio webcast will be available on the company's website, with replays accessible for 30 days post-event. IDEAYA focuses on developing targeted therapies for cancer.
Read more →IDYA▲ +6.7%on this news
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
Read more →IDYA▲ +6.7%on this news
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. has announced its participation in two upcoming investor relations events in June 2025. The events include the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference, where CEO Yujiro S. Hata will participate in fireside chats. A live audio webcast will be available for both events.
Read more →IDYA▼ -13.3%on this news
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced FDA IND clearance for IDE849, a DLL3-targeting ADC, initiating a Phase 1 clinical trial for solid tumors. The trial will evaluate IDE849's efficacy in small cell lung cancer (SCLC) and neuroendocrine tumors (NETs). Preliminary data show promise, with multiple partial responses observed. Future presentations are planned for Q3 2025, detailing clinical data and combination therapy results.
Read more →IDYA▼ -13.3%on this news
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update ~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial...
IDEAYA Biosciences reported strong financial results for Q1 2025, with approximately $1.05 billion in cash and marketable securities. The company is making significant progress in its darovasertib program, having enrolled over 300 patients in a registrational trial. Additionally, IDEAYA received FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant uveal melanoma, with multiple clinical data updates expected in 2025.
Read more →IDYA▼ -13.3%on this news
IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
IDEAYA Biosciences Announces US FDA IND Clearance for IDE849, a Potential First in Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Read more →IDYA▼ -13.3%on this news
IDEAYA Biosciences, Inc Reports First Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports First Quarter 2025 Financial Results and Provides Business Update
Read more →IDYA▼ -13.3%on this news
IDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) March 31
IDEAYA Biosciences, Inc. reported its financial results for the first quarter of 2025, highlighting a robust cash position of approximately $1.05 billion. The company is advancing its darovasertib program with over 300 patients currently enrolled in a pivotal trial, targeting to file for accelerated approval by the end of 2025. IDEAYA also made significant progress with its clinical pipeline, including new data expected from various trials throughout the year. The company has a promising future with multiple updates and IND filings planned for several innovative programs.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in two upcoming investor relations events in May 2025. The events include a fireside chat at the Barclays Hosted Catalyst & Key Debate Calls and the RBC Capital Markets Global Healthcare Conference. CEO Yujiro S. Hata will lead discussions, emphasizing the company's focus on precision medicine and targeted therapeutics.
Read more →IDYAIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025 Clinical endpoints ...
IDEAYA Biosciences announced a successful FDA Type D meeting regarding the Phase 3 trial design for darovasertib as neoadjuvant therapy for primary uveal melanoma. The trial aims to evaluate safety and efficacy, focusing on eye preservation and vision loss as primary endpoints. The company plans to initiate the trial in H1 2025, with a total enrollment of approximately 520 patients across two cohorts.
Read more →IDYAIDEAYA Biosciences Announces Phase 1 2 Expansion for IDE397 and Trodelvy R Combination in MTAP Deletion Urothelial Cancer
IDEAYA Biosciences Announces Phase 1 2 Expansion for IDE397 and Trodelvy R Combination in MTAP Deletion Urothelial Cancer
Read more →IDYAIDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced the initiation of a Phase 1/2 study expansion for IDE397, a MAT2A inhibitor, in combination with Trodelvy for treating MTAP-deletion urothelial cancer. This decision is based on preliminary safety and efficacy data, addressing a significant unmet medical need. The combination is investigational and not yet approved by regulatory bodies.
Read more →IDYA▼ -9.8%on this news
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
Read more →IDYA▼ -9.8%on this news
IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced its participation in two upcoming investor relations events in April 2025. The events include a fireside chat at the RBCCM Ophthalmology Conference and another at the Stifel Virtual Targeted Oncology Forum. These sessions will feature key executives discussing the company's advancements in precision medicine oncology.
Read more →IDYAIDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has received FDA Breakthrough Therapy designation for darovasertib, aimed at treating neoadjuvant uveal melanoma. This designation is based on promising Phase 2 trial data showing high rates of tumor shrinkage and eye preservation. The company plans to initiate a Phase 3 registrational study in early 2025, targeting a patient population with significant unmet medical needs.
Read more →IDYAIDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
Read more →IDYAIDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor 4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR...
IDEAYA Biosciences announced multiple presentations at AACR 2025, including an oral presentation on IDE275 (GSK959), a Werner Helicase inhibitor. The drug has shown promising preclinical results in treating MSI-H solid tumors and is currently in a Phase 1 trial. IDEAYA's collaboration with GSK involves shared R&D costs and potential milestone payments.
Read more →IDYA▼ -7%on this news
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI ML Enabled Drug Discovery for Unprecedented First in Class Oncology Targets
Read more →IDYA▼ -7%on this news
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced a collaboration with ATTMOS to enhance AI/ML-enabled drug discovery for challenging oncology targets. This partnership aims to develop a computational platform that integrates structural biology and high-performance computing to improve the identification of drug candidates. The collaboration seeks to address the limitations of current drug discovery methods and accelerate the development of novel therapeutics.
Read more →IDYA▼ -5.4%on this news
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has entered a collaboration with Gilead Sciences to evaluate the combination of IDE397 and Trodelvy in treating MTAP-deletion non-small cell lung cancer (NSCLC). This partnership aims to explore the efficacy and safety of this potential first-in-class treatment. The prevalence of MTAP-deletion in NSCLC is approximately 15%, highlighting a significant patient population for this study.
Read more →IDYA▼ -5.4%on this news
IDEAYA Biosciences, Inc. Condensed Balance Sheet Data ( in thousands ) December 31
IDEAYA Biosciences, Inc. reported its fourth quarter and full year 2024 financial results, highlighting significant enrollment in key clinical trials including a potential registration-enabling trial for darovasertib in 1L HLA-A2-negative metastatic uveal melanoma. The company is on track to announce multiple clinical data updates throughout 2025, supported by a strong financial position with approximately $1.1 billion in cash reserves. Additionally, IDEAYA revealed plans to advance several new compounds into clinical studies, including IDE397 and IDE892, while also winding down a collaboration with Amgen.
Read more →IDYA▼ -5.4%on this news
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
Read more →IDYA▼ -5.4%on this news
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95...
IDEAYA Biosciences reported its financial results for Q4 and full year 2024, highlighting significant progress in its clinical pipeline. The company has enrolled over 230 patients in a trial for first-line HLA-A2-negative metastatic uveal melanoma (MUM) and anticipates key data readouts in 2025. IDEAYA's financial position remains strong with approximately $1.1 billion in cash, expected to fund operations into 2028. However, the company reported a significant increase in net loss compared to the previous year.
Read more →IDYA▼ -5.4%on this news
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has appointed Joshua Bleharski, Ph.D., as Chief Financial Officer. Dr. Bleharski, previously with J.P. Morgan, brings nearly 17 years of investment banking experience in the biopharma sector. He will help advance IDEAYA's oncology pipeline, which includes six clinical and three preclinical programs. His transition to the role is expected to be completed by early May.
Read more →IDYAIDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. has announced its participation in two upcoming investor relations events in February 2025. The events include the Oppenheimer 35th Annual Healthcare Life Sciences Conference and Citi's 2025 Virtual Oncology Leadership Summit, featuring CEO Yujiro S. Hata. Live audio webcasts will be available for those unable to attend.
Read more →IDYAIDEAYA Biosciences Announces Participation at the 43rd Annual J P Morgan Healthcare Conference and 2025 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 43rd Annual J P Morgan Healthcare Conference and 2025 Corporate Guidance
Read more →IDYAIDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2025. The company provided optimistic corporate guidance, highlighting $1.2 billion in cash reserves to support operations through at least 2028. Key clinical updates include advancements in their darovasertib program for metastatic uveal melanoma and other promising oncology therapies.
Read more →IDYAIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors Exclusive global license outside of Greater China for SHR-4849, a
IDEAYA Biosciences has signed an exclusive global licensing agreement with Hengrui Pharma for SHR-4849, a DLL3-targeting ADC in development for small cell lung cancer (SCLC) and neuroendocrine tumors (NET). SHR-4849 has shown promising results in Phase 1 trials, demonstrating a high response rate among treated SCLC patients. The agreement includes a potential total of $1.045 billion in payments and royalties for Hengrui Pharma. IDEAYA plans to file a U.S. IND for SHR-4849 within the next six months, aiming to address significant gaps in treatment for these solid tumors.
Read more →IDYAIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has secured an exclusive global license for SHR-4849, a DLL3-targeting ADC, from Hengrui Pharma. This drug is aimed at treating small cell lung cancer (SCLC) and neuroendocrine tumors (NETs), showing promising early clinical results. IDEAYA plans to file for a US IND in the first half of 2025. The partnership includes significant financial terms, with Hengrui eligible for up to $1.045 billion in payments.
Read more →IDYAIDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced that the Independent Data Monitoring Committee has recommended a move-forward dose for the darovasertib and crizotinib combination in a Phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma. The trial has enrolled over 185 patients and has received FDA Fast Track designation. This recommendation supports the advancement towards potential accelerated approval based on progression-free survival.
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First in Class KAT6 7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has nominated IDE251 as a development candidate, a potential first-in-class KAT6/7 dual inhibitor aimed at treating breast and lung cancers with 8p11 amplification. The drug has shown promising anti-tumor activity in preclinical models, and an IND submission is targeted for 2025. The company is optimistic about IDE251's potential to benefit patients with specific genetic profiles.
Read more →IDYAIDEAYA Announces Agenda for Investor R D Day Webcast on December 16, 2024
IDEAYA Announces Agenda for Investor R D Day Webcast on December 16, 2024
Read more →IDYAIDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced the agenda for its upcoming virtual Investor R&D Day on December 16, 2024. The event will feature presentations on its precision medicine oncology pipeline, including updates on several promising drug candidates. Key opinion leaders will also participate, discussing treatment paradigms and new approaches in oncology.
Read more →IDYAIDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Read more →IDYAIDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA®...
IDEAYA Biosciences has initiated a Phase 1 clinical trial evaluating IDE161 in combination with KEYTRUDA for endometrial cancer patients. The trial will assess the safety and efficacy of this combination in patients with MSI-high and MSS tumors. IDE161 is a potential first-in-class PARG inhibitor, showing promise in preclinical studies.
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has nominated IDE892 as a development candidate, a selective MTA-cooperative PRMT5 inhibitor. The drug demonstrates significant antitumor activity and favorable drug properties, with ongoing studies aimed at an IND filing in mid-2025. This nomination marks the seventh candidate in IDEAYA's precision medicine oncology pipeline.
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor
Read more →IDYAIDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in two upcoming investor relations events in December 2024. The company will feature CEO Yujiro S. Hata in fireside chats at the Citi Global Healthcare Conference and the Evercore HealthCONx Conference. These events aim to enhance investor engagement and provide insights into IDEAYA's precision medicine initiatives.
Read more →IDYAIDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has appointed Stu Dorman as Chief Commercial Officer, leveraging his extensive experience in oncology commercialization. Dorman has a successful history with leading biopharmaceutical companies and is expected to enhance IDEAYA's commercial strategy, particularly for darovasertib and other pipeline products. His leadership is anticipated to strengthen the company's position in the oncology market.
Read more →IDYAIDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Read more →IDYAIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R D Day
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R D Day
Read more →IDYAIDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced its participation in the Jefferies London Healthcare Conference on November 19, 2024, and plans to host an Investor R&D Day on December 16, 2024. The events will feature discussions on the company's preclinical and clinical pipeline, highlighting its commitment to precision medicine in oncology. A live webcast of the conference will be available, with a replay accessible for 30 days.
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC and Option Exercise with Biocytogen
Read more →IDYAIDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen Nominated IDE034 (BCG034) as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC)...
IDEAYA Biosciences has nominated IDE034, a bispecific antibody drug conjugate targeting B7H3/PTK7, as a development candidate. The company exercised an option for an exclusive worldwide license from Biocytogen and plans to file for an IND in 2025. IDE034 could be developed both as a monotherapy and in combination with IDE161, targeting multiple solid tumors.
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update • Enrollment in darovasertib + crizotinib 1L HLA-A2+ MUM potential Ph2/3 registration-enabling trial is ahead of s
IDEAYA Biosciences reported its third quarter 2024 results, highlighting significant progress in its clinical pipeline. The company announced that enrollment for its darovasertib trial exceeded 150 patients and that positive interim results were achieved for ocular tumor shrinkage and eye preservation. Additionally, IDEAYA received IND clearance for its Werner Helicase candidate and successfully raised $302.4 million in financing. The company is on track to initiate key trials in early 2025.
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Enrollment in darovasertib + crizotinib 1L HLA-A2(-) MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150...
IDEAYA Biosciences reported strong progress in its clinical trials, particularly with darovasertib, which has exceeded enrollment targets for its Phase 2/3 trial. The company successfully held a Type C meeting with the FDA, paving the way for a Phase 3 trial in neoadjuvant uveal melanoma. Financially, IDEAYA is well-positioned with $1.2 billion in cash, despite reporting a net loss of $51.8 million for the third quarter of 2024.
Read more →IDYAIDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
IDEAYA Biosciences Announces IND Clearance for Werner Helicase Development Candidate IDE275 GSK959 for a Phase 1 Study in MSI High Solid Tumors
Read more →IDYAIDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing...
IDEAYA Biosciences has received IND clearance from the FDA for IDE275 (GSK959), a Werner Helicase inhibitor, allowing it to initiate a Phase 1 clinical trial targeting MSI-High solid tumors. The drug has shown promising preclinical results, and IDEAYA stands to gain significant financial milestones as the program progresses. The trial is expected to start in Q4 2024.
Read more →IDYAIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
Read more →IDYAIDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 ~33% ORR by RECIST 1.1: 1 CR + 8 PRs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) MTAP-deletion UC and NSCLC...
IDEAYA Biosciences announced positive interim Phase 1 expansion data for IDE397, a MAT2A inhibitor, in treating MTAP-deletion urothelial and lung cancers. The study reported a 33% overall response rate, with no serious adverse events at the expansion dose. The company plans to expand the study in combination with Trodelvy in Q4 2024, highlighting the unmet need for therapies targeting MTAP-deletion solid tumors.
Read more →IDYAIDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36 th Edition of the EORTC-NCI-AACR Symposium South San Francisco, CA
IDEAYA Biosciences has announced the late-breaking oral presentation of the Phase 1 expansion results of its first-in-class MAT2A inhibitor, IDE397, targeting MTAP-deleted lung and urothelial cancers. This presentation will take place at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain from October 23 to 25, 2024. Additionally, IDEAYA will showcase other preclinical data on its therapies through poster presentations. The event is expected to enhance awareness of IDEAYA's innovative oncology approaches.
Read more →IDYAIDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced a late-breaking oral presentation of IDE397 Phase 1 expansion results targeting MTAP-deletion lung and urothelial cancer. The presentation will occur at the EORTC-NCI-AACR Symposium in Barcelona on October 25, 2024. Additionally, IDEAYA will showcase preclinical data for its MAT2A and PARG programs during the event.
Read more →IDYAIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with...
IDEAYA Biosciences announced positive interim Phase 2 data for darovasertib in neoadjuvant uveal melanoma, showing significant tumor shrinkage and eye preservation rates. The company successfully held an FDA Type C meeting, paving the way for a Phase 3 registrational trial. The trial aims to enroll approximately 400 patients, targeting a high unmet medical need in this area.
Read more →IDYAIDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
Read more →IDYAIDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will conduct an investor webcast on September 23, 2024, to present interim Phase 2 data for darovasertib and provide a regulatory update following an FDA Type C meeting. The presentation will cover clinical efficacy, baseline characteristics, and adverse event profiles related to darovasertib in the treatment of neoadjuvant uveal melanoma. Key executives will participate in the webcast, which will be accessible via the company's Investor Relations portal.
Read more →IDYAIDEAYA Biosciences Appoints Douglas B Snyder as Senior Vice President, General Counsel
IDEAYA Biosciences Appoints Douglas B Snyder as Senior Vice President, General Counsel
Read more →IDYAIDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has appointed Douglas B. Snyder as Senior Vice President and General Counsel. Snyder, who has over 25 years of legal experience in healthcare, will lead the company's legal functions as it prepares for the commercialization of Darovasertib and expands its clinical pipeline. His previous roles include significant positions at GW Pharmaceuticals and Actelion Pharmaceuticals.
Read more →IDYAIDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Read more →IDYAIDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. CEO Yujiro S. Hata will engage in a fireside chat, hosted by Judah Frommer. A live audio webcast will be available, with a replay accessible for 30 days post-event. This participation highlights IDEAYA's commitment to oncology and precision medicine.
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update • Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and 50 patients enr
IDEAYA Biosciences, Inc. reported its financial results for Q2 2024, highlighting progress in its clinical programs. The company achieved triple-digit enrollment in the Phase 2/3 trial of darovasertib for neoadjuvant uveal melanoma and reported preliminary proof-of-concept for IDE397 in MTAP-deletion cancers. With a solid cash position of $952.7 million, IDEAYA is well-funded for its pipeline advancements, including plans for an investor R&D day later this year. Upcoming milestones include a Type C meeting with the FDA and updates on multiple clinical trials in H2 2024.
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM study ...
IDEAYA Biosciences reported its Q2 2024 financial results, highlighting significant progress in clinical trials, particularly for darovasertib and IDE397. The company achieved triple-digit enrollment in a Phase 2/3 trial and presented promising data for IDE397 in MTAP-deletion cancers. Despite a net loss of $52.8 million, IDEAYA maintains a strong cash position of $952.7 million, supporting its ongoing research and development efforts.
Read more →IDYAIDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
IDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
Read more →IDYAintellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further descriptio
IDEAYA Biosciences has announced a collaboration with Biocytogen Pharmaceuticals for a first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate program. The agreement allows IDEAYA exclusive global rights to develop this therapeutic, which targets multiple solid tumors and has potential for combination with their existing DNA Damage Repair pipeline. The partnership aims to leverage Biocytogen's advanced technology to enhance therapeutic precision. IDEAYA expects to nominate a development candidate in the latter half of 2024.
Read more →IDYAIDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has entered an option and license agreement with Biocytogen for a first-in-class B7H3/PTK7 bispecific antibody drug conjugate (BsADC) program. This collaboration aims to develop therapies targeting multiple solid tumors, leveraging Biocytogen's advanced technology. IDEAYA plans to nominate a development candidate by the second half of 2024, with significant financial milestones outlined in the agreement.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will participate in the 2024 BTIG Virtual Biotechnology Conference on August 5, 2024. CEO Yujiro S. Hata will engage in a fireside chat hosted by Justin Zelin. The event will be accessible via a live audio webcast, showcasing IDEAYA's commitment to precision medicine in oncology.
Read more →IDYA▲ +6.2%on this news
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Read more →IDYA▲ +6.2%on this news
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 8,355,714 shares of its common stock at a...
IDEAYA Biosciences, Inc. has successfully closed its underwritten public offering of 8,355,714 shares at $35.00 per share, raising approximately $302.4 million. The offering included the full exercise of an option by underwriters to purchase additional shares. This move reflects strong market interest and positions IDEAYA for future growth.
Read more →IDYAIDEAYA Announces Pricing of Public Offering
IDEAYA Announces Pricing of Public Offering
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre Funded Warrants
IDEAYA Announces Proposed Public Offering of Common Stock and Pre Funded Warrants
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in...
IDEAYA Biosciences, Inc. announced a proposed public offering of up to $200 million in common stock and pre-funded warrants. The offering is subject to market conditions, with a 30-day option for underwriters to purchase additional shares. The funds are intended to support the company's precision medicine oncology initiatives.
Read more →IDYAIDEAYA Announces Pricing of Public Offering IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants....
IDEAYA Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, totaling 7,228,572 shares of common stock, priced at $35.00 each. This offering is expected to raise approximately $263 million before expenses, with a closing date anticipated around July 11, 2024. The investment banks J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, and RBC Capital Markets are set to manage the offering. IDEAYA has also granted underwriters a 30-day option to purchase additional shares.
Read more →IDYA▲ +15.3%on this newsshared move
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First in Class MAT2A Inhibitor in MTAP Deletion Urothelial and Lung Cancer
Read more →IDYA▲ +15.3%on this newsshared move
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC...
IDEAYA Biosciences has announced positive interim results from its Phase 2 trial of IDE397, a potential first-in-class MAT2A inhibitor, showing a 39% overall response rate in patients with MTAP-deletion urothelial and non-small cell lung cancer. The trial reported a favorable safety profile, with no serious adverse events and a high disease control rate of 94%. The company aims to address the significant unmet need in these cancer types, as there are currently no FDA-approved therapies for MTAP-deletion solid tumors.
Read more →IDYAIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
Read more →IDYAIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced an investor webcast scheduled for July 8, 2024, to present clinical data updates on IDE397, a potential first-in-class MAT2A inhibitor. The presentation will cover various aspects of the Phase 2 expansion dose in patients with MTAP-deletion urothelial and non-small cell lung cancer. IDEAYA is also advancing multiple preclinical programs related to MTAP-deletion solid tumors.
Read more →IDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE397 in combination with Trodelvy for treating MTAP-deletion bladder cancer. The trial will assess safety, tolerability, and efficacy. This combination therapy targets specific cancer pathways, potentially improving outcomes for patients with this genetic deletion. The study is part of a broader clinical program involving IDE397.
Read more →IDYAIDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
IDEAYA Biosciences Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy R Combination in MTAP Deletion Bladder Cancer
Read more →IDYAIDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First in Class Phase 2 MAT2A Inhibitor Targeting MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024,...
IDEAYA Biosciences has announced updates on its IDE397 clinical program, a potential first-in-class MAT2A inhibitor targeting MTAP-deletion solid tumors. The company is expanding its Phase 2 monotherapy trials in MTAP bladder cancer and lung cancer, with over 35 clinical trial sites activated worldwide. A clinical data update is expected in the second half of 2024, detailing efficacy and safety results.
Read more →IDYA▲ +6.4%on this news
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median...
IDEAYA Biosciences announced positive results from its Phase 2 trial of darovasertib for neoadjuvant treatment in uveal melanoma, presented at ASCO 2024. The trial showed a 75% eye preservation rate and significant tumor shrinkage in patients. The company plans to meet with the FDA in H2 2024 to discuss potential registrational trials.
Read more →IDYA▲ +6.4%on this news
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company Sponsored Neoadjuvant Study
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company Sponsored Neoadjuvant Study
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will participate in two significant investor relations events in June 2024. The events include the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference, where CEO Yujiro S. Hata will engage in fireside chats. Live audio webcasts will be available for interested investors.
Read more →IDYAIDEAYA Biosciences Appoints Daniel A Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
IDEAYA Biosciences Appoints Daniel A Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
Read more →IDYAIDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has appointed Daniel A. Simon as Chief Business Officer, effective August 2024. Simon, who has over 18 years of experience in life sciences and strategy consulting, is expected to enhance the company's corporate strategy and business development. His expertise will support IDEAYA's goal of delivering a diversified pipeline targeting biomarker-defined cancers.
Read more →IDYA▼ -7.1%on this newsshared move
C O R R E C T I O N IDEAYA Biosciences, Inc
C O R R E C T I O N IDEAYA Biosciences, Inc
Read more →IDYA▼ -7.1%on this newsshared move
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma ~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage...
IDEAYA Biosciences announced promising results from its Phase 2 trial of darovasertib in treating neoadjuvant uveal melanoma. In the study, 15 patients scheduled for enucleation received darovasertib, leading to a 67% eye preservation rate and a median tumor shrinkage of approximately 45% after six months. The treatment was generally well tolerated, with most adverse events being mild; however, 13% of patients experienced Grade 3 adverse events. More detailed findings will be presented at the ASCO 2024 oral presentation in June.
Read more →IDYAIDEAYA Biosciences, Inc Reports First Quarter 2024 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports First Quarter 2024 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in...
IDEAYA Biosciences reported its first quarter 2024 financial results, highlighting significant advancements in its clinical pipeline, including a presentation at ASCO 2024 for darovasertib in neoadjuvant uveal melanoma. The company has a strong cash position of $941.4 million, expected to fund operations into 2028. However, it also reported a net loss of $39.6 million and no collaboration revenue for the quarter.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands ) March 31
IDEAYA Biosciences, Inc. has provided a business update and announced its first-quarter financial results for 2024. The company is advancing several clinical programs, including darovasertib for uveal melanoma and IDE397 for MTAP-deletion solid tumors. IDEAYA aims to present data at ASCO 2024 regarding ongoing trials and anticipates further developments in its clinical pipeline. With a strong cash position, IDEAYA is well-positioned for continued growth and development in the oncology space.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in the RBC Capital Markets Global Healthcare Conference on May 14, 2024. CEO Yujiro S. Hata will engage in a fireside chat hosted by Gregory Renza. A live audio webcast will be available, along with a replay for 30 days post-event. The company focuses on precision medicine and targeted therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
Read more →IDYAIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Read more →IDYAIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced that interim results from a Phase 2 trial of darovasertib for neoadjuvant treatment in uveal melanoma will be presented at ASCO 2024. The oral presentation is scheduled for June 3, 2024, highlighting the safety and efficacy of the treatment. The abstract will be available on May 23, 2024.
Read more →IDYAIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has selected a Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer (NSCLC). This decision is based on a favorable adverse event profile and promising preliminary clinical efficacy, including multiple partial responses. The company aims to address the significant unmet medical need in this patient population.
Read more →IDYAIDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in the Stifel Virtual Targeted Oncology Forum on April 16, 2024. CEO Yujiro S. Hata will engage in a fireside chat hosted by Benjamin Burnett, Ph.D. The event will be accessible via a live audio webcast, with a replay available for 30 days. IDEAYA focuses on precision medicine and targeted therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
Read more →IDYAIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced a clinical collaboration with Merck to evaluate its investigational PARG inhibitor, IDE161, in combination with KEYTRUDA for patients with endometrial cancer. This Phase 1 trial will focus on both MSI-high and MSS cancer types. IDE161 has shown early promise in tumor shrinkage and has received FDA Fast-Track designation for certain cancers.
Read more →IDYAIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced its participation in two upcoming investor relations events in March 2024. The events include the Leerink Partners Global Biopharma Conference and the Jefferies Biotech on the Bay Summit, where CEO Yujiro S. Hata will speak. The company aims to showcase its advancements in precision medicine and targeted therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
Read more →IDYA▼ -6.6%on this news
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Read more →IDYA▼ -6.6%on this news
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase ...
IDEAYA Biosciences reported its fourth quarter and full-year 2023 financial results, highlighting plans for two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma by mid-2024. The company also announced ongoing collaborations with Gilead Sciences and Amgen, alongside a strong cash balance of $632.6 million, expected to support operations into 2028. Despite a net loss increase, IDEAYA remains focused on advancing its precision medicine pipeline.
Read more →IDYA▼ -6.6%on this news
About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach
IDEAYA Biosciences announced a clinical collaboration with Merck to evaluate IDE161, a PARG inhibitor, in combination with KEYTRUDA for treating endometrial cancer. This Phase 1 trial targets both microsatellite instability-high and stable forms of the cancer. IDE161 is currently undergoing a monotherapy expansion stage with prior encouraging results noted in various solid tumors. The collaboration allows IDEAYA to advance its investigational treatments while leveraging Merck's resources for the trial.
Read more →IDYA▼ -6.6%on this news
IDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands ) December 31
IDEAYA Biosciences, Inc. reported robust financial results for Q4 and full-year 2023, focusing on its precision medicine initiatives. The company is targeting several important clinical updates and collaborations for its lead candidates, including darovasertib and IDE397, set for mid-2024. IDEAYA has a substantial cash balance to support operations through 2028, which underscores its commitment to advancing multiple first-in-class oncology programs.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will participate in two investor relations events in February 2024. The first is the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, followed by Citi's 2024 Virtual Oncology Leadership Summit on February 21. The company aims to showcase its advancements in precision medicine and targeted therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
Read more →IDYA▲ +6.6%on this news
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2024. The company provided updates on its 2024 corporate guidance, highlighting a robust financial position and ongoing clinical trials, including a Phase 2/3 trial for darovasertib and crizotinib in metastatic uveal melanoma. IDEAYA also anticipates significant clinical updates and patient enrollment in various studies throughout the year.
Read more →IDYA▲ +6.6%on this news
IDEAYA Biosciences Announces Participation at the 42nd Annual J P Morgan Healthcare Conference and 2024 Corporate Guidance
IDEAYA Biosciences Announces Participation at the 42nd Annual J P Morgan Healthcare Conference and 2024 Corporate Guidance
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in the Barclays Lunchtime Fireside Chat Series on December 5, 2023. CEO Yujiro S. Hata will be featured in the event, which will include a live audio webcast. The company focuses on precision medicine and targeted therapeutics, enhancing its visibility among investors.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
Read more →IDYAUnder the clinical study collaboration and supply agreement, Gilead will provide drug supply to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial. IDEAYA and Gilead each retain all commercial ri
IDEAYA Biosciences has announced a clinical study collaboration with Gilead Sciences to evaluate the efficacy and safety of a combination therapy involving IDE397 and Trodelvy for treating MTAP-deletion bladder cancer. Under the collaboration, IDEAYA will sponsor a Phase 1 clinical trial, with Gilead providing Trodelvy. This collaboration focuses on a patient population with a high unmet medical need, given the lack of approved therapies for MTAP-deletion bladder cancer. The use of a MAT2A inhibitor alongside an ADC could potentially lead to innovative treatment options for patients with solid tumors exhibiting MTAP deletions.
Read more →IDYAIDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with...
IDEAYA Biosciences has entered a clinical study collaboration with Gilead Sciences to evaluate the combination of IDE397, a MAT2A inhibitor, and Trodelvy in treating MTAP-deletion bladder cancer. The Phase 1 trial will assess the efficacy and safety of this combination, targeting a patient population with a significant unmet medical need. The collaboration aims to leverage the strengths of both companies in addressing this challenging cancer type.
Read more →IDYAIDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy R and IDE397 Combination in MTAP Deletion Bladder Cancer
Read more →IDYAIDEAYA Announces Agenda for Investor R D Day Webcast on December 4, 2023
IDEAYA Announces Agenda for Investor R D Day Webcast on December 4, 2023
Read more →IDYAIDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has announced the agenda for its Investor R&D Day webcast scheduled for December 4, 2023. The event will highlight the company's synthetic lethality pipeline, featuring presentations from management and key opinion leaders. Topics will include updates on clinical programs and future initiatives, including a planned IND submission for the Werner Helicase program.
Read more →IDYAIDEAYA Biosciences, Inc. Condensed Bal ance Sheet Data ( in thousands )
IDEAYA Biosciences, Inc. reported its third-quarter 2023 financial results, showing a strong balance sheet with $511.1 million in cash and marketable securities. The company is advancing multiple clinical trials, including a Phase 2/3 trial for darovasertib in metastatic uveal melanoma and ongoing studies for IDE397 and IDE161 targeting various solid tumors. IDEAYA has received Fast Track Designation for IDE161 and is planning further development with collaborations with GSK. An upcoming Investor R&D Day is set for December 4, 2023, to outline future strategies and progress.
Read more →IDYAIDEAYA Biosciences, Inc Reports Third Quarter 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Third Quarter 2023 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million...
IDEAYA Biosciences reported its Q3 2023 financial results, highlighting a strong balance sheet with over $511 million in cash and securities. The company is advancing multiple clinical trials, including a Phase 2/3 trial for darovasertib in metastatic uveal melanoma and a Phase 1/2 trial for IDE397 in MTAP-deletion solid tumors. IDEAYA also received Fast Track Designation for IDE161 in certain cancers, showcasing its commitment to precision medicine.
Read more →IDYA▲ +6.3%on this news
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences announced its participation in the Jefferies London Healthcare Conference and plans to host an Investor R&D Day in December 2023. The R&D Day will feature insights into IDEAYA's synthetic lethality pipeline and collaborations with GSK. This event aims to showcase clinical development opportunities and future initiatives in targeted therapeutics.
Read more →IDYA▲ +6.3%on this news
IDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Jefferies London Healthcare Conference
IDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Jefferies London Healthcare Conference
Read more →IDYA▼ -5.5%on this newsshared move
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a...
IDEAYA Biosciences has successfully closed its underwritten public offering, selling 5,797,872 shares at $23.50 each, raising approximately $143.8 million. The offering included the full exercise of an option by underwriters to purchase additional shares. This capital infusion is expected to support IDEAYA's precision medicine initiatives in oncology.
Read more →IDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in...
IDEAYA Biosciences announced a proposed public offering of up to $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase an additional $18.8 million in shares. The offering is contingent on market conditions, and details will be filed with the SEC.
Read more →IDYA▲ +5.5%on this newsshared move
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
IDEAYA Announces Top Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ 11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
Read more →IDYA▲ +5.5%on this newsshared move
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline 60% confirmed ORR% by RECIST 1.1 in HLA-A2(+) in 1L MUM, and 42% confirmed ORR% by RECIST 1.1 in HLA-A2(-) in 1L MUM Median PFS of 7.1 months in 1L...
IDEAYA Biosciences presented promising Phase 2 results at ESMO 2023 for the combination of darovasertib and crizotinib in metastatic uveal melanoma (MUM). The treatment showed a 60% confirmed overall response rate in HLA-A2(+) patients and a 94% ctDNA molecular response rate. The safety profile was manageable, supporting the potential for accelerated approval in a patient population lacking FDA-approved therapies. However, the data remains preliminary and subject to further validation.
Read more →IDYA▲ +7.6%on this news
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
Read more →IDYA▲ +7.6%on this news
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma Proffered paper oral presentation at ESMO 2023 scheduled for Monday, October 23, 2023, at 8:50 am CEST will be presented by Dr. Meredith McKean, Sara ...
IDEAYA Biosciences announced a proffered paper oral presentation at ESMO 2023, scheduled for October 23, 2023. The presentation will cover Phase 2 clinical data on the combination of darovasertib and crizotinib for metastatic uveal melanoma. Results indicate a manageable safety profile and clinical efficacy that surpasses current treatment standards. The data supports ongoing registrational studies for potential accelerated approval.
Read more →IDYAIDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ 11 Metastatic Cutaneous Melanoma
Read more →IDYAIDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma Initiated Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma based on preliminary clinical...
IDEAYA Biosciences has initiated a Phase 2 expansion of the darovasertib and crizotinib combination for patients with GNAQ/11 metastatic cutaneous melanoma. This decision follows preliminary clinical efficacy observed in this patient population, which currently lacks FDA-approved therapies. The expansion aims to address the significant unmet medical need and potentially increase the patient population benefiting from this treatment.
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R D Day
IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R D Day
Read more →IDYAIDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day Selected a Werner Helicase Inhibitor Development Candidate in collaboration with GSK Observed monotherapy complete responses preclinically in...
IDEAYA Biosciences has nominated a Werner Helicase Inhibitor as a development candidate in collaboration with GSK. The inhibitor has shown promising preclinical results, including complete responses in various cancer models. IDEAYA is targeting an IND submission in 2024, with potential financial milestones totaling up to $465 million. An Investor R&D Day is planned for Q4 2023.
Read more →IDYAIDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with HR+, Her2-, BRCA1/2 mutant advanced or metastatic breast...
IDEAYA Biosciences has received Fast Track designation from the FDA for IDE161, targeting advanced or metastatic HR+, Her2-, BRCA1/2 mutant breast cancer. This marks the second indication for IDE161, complementing its designation for ovarian cancer. The ongoing Phase 1 trial shows promise with preliminary tumor shrinkage in patients. IDEAYA plans to provide updates on the clinical program in Q4 2023.
Read more →IDYAIDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
Read more →IDYAIDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Read more →IDYAIDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patients with BRCA1/2 mutant advanced or metastatic ovarian cancer who...
IDEAYA Biosciences has received Fast Track designation from the FDA for IDE161, a PARG inhibitor aimed at treating advanced or metastatic ovarian cancer in patients with BRCA1/2 mutations. This designation allows for expedited regulatory review and potential accelerated approval. The ongoing Phase 1 trial has shown preliminary efficacy, particularly in HRD+ tumors, supporting further development.
Read more →IDYAIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
Read more →IDYAIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors Initiated IDE161 Phase 1 expansion based on preliminary tumor shrinkage observed in multiple HRD solid tumor patients, including an endometrial...
IDEAYA Biosciences has initiated a Phase 1 expansion of IDE161, a potential first-in-class PARG inhibitor, based on preliminary tumor shrinkage in HRD solid tumors. The expansion will focus on ER+, Her2(-) breast cancer and HRD+ ovarian cancer. Early clinical data indicate promising target engagement and tumor regression. Updates on the clinical program are expected in the second half of 2023.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences will participate in two significant investor relations events in September 2023. The Citi 18th Annual BioPharma Conference on September 6 will feature CFO Paul Stone, while the Morgan Stanley 21st Annual Global Healthcare Conference on September 11 will include a fireside chat with CEO Yujiro S. Hata. Live webcasts of these events will be available on IDEAYA's website.
Read more →IDYAIDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 IDE705
IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 IDE705
Read more →IDYAIDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences has received FDA clearance for an IND application for GSK101 (IDE705), a Pol Theta Helicase inhibitor. This drug will be evaluated in a GSK-sponsored Phase 1/2 clinical trial in combination with niraparib for patients with advanced solid tumors harboring HR mutations. IDEAYA is set to receive a $7 million milestone payment upon IND acceptance, with potential future milestones totaling up to $950 million.
Read more →IDYAIDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
IDEAYA Announces First Patient In for Company Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in Neo Adjuvant Uveal Melanoma
Read more →IDYAIDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary...
IDEAYA Biosciences has initiated a Phase 2 clinical trial for darovasertib in uveal melanoma, with the first patient dosed. Preliminary results indicate tumor shrinkage in all patients treated, suggesting strong anti-tumor activity. The trial aims to evaluate darovasertib's effectiveness as both neoadjuvant and adjuvant therapy, with updates expected in Q4 2023.
Read more →IDYAIDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into...
IDEAYA Biosciences reported strong financial results for Q2 2023, with $510.1 million in cash expected to sustain operations through 2027. The company has initiated several clinical trials, including a Phase 2/3 trial for darovasertib in metastatic uveal melanoma. Despite a net loss of $27.9 million, IDEAYA remains optimistic about its clinical pipeline and upcoming milestones.
Read more →IDYAIDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
IDEAYA and Amgen Achieve First Patient In for Clinical Evaluation of IDE397 MAT2A and AMG 193 PRMT5 MTA Combination in MTAP Tumors
Read more →IDYAIDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors - First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in...
IDEAYA Biosciences and Amgen have initiated a Phase 1/2 clinical trial for the combination of IDE397 and AMG 193 in patients with MTAP-deleted tumors. The trial aims to evaluate the safety and efficacy of this combination therapy, which has shown promising preliminary results in earlier studies. The collaboration is expected to leverage both companies' strengths in targeted therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
IDEAYA Biosciences, Inc. announced its participation in the BTIG Virtual Biotechnology Conference on August 8, 2023. CEO Yujiro S. Hata will be featured in a fireside chat during the event. The company focuses on precision medicine and targeted therapeutics, utilizing molecular diagnostics to select patient populations for its therapies.
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event
Read more →IDYAIDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy
Read more →IDYAIDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP Deletion Solid Tumor Types
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP Deletion Solid Tumor Types
Read more →IDYAIDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
Read more →IDYAIDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
IDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma  Amended cl
IDEAYA Biosciences has extended its collaboration with Pfizer to support a Phase 2/3 registrational trial evaluating the combination therapy of darovasertib and crizotinib for first-line metastatic uveal melanoma (MUM). The trial is expected to initiate in Q2 2023, with progression-free survival as the primary endpoint for potential accelerated approval. IDEAYA is currently assessing the drug combination's efficacy in an ongoing Phase 2 trial, which has shown promising results. This collaboration underscores IDEAYA's commitment to developing targeted therapies in oncology.
Read more →IDYA▲ +14.6%on this news
IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update • Strong balance sheet of $351.2 million of cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. has reported its first quarter 2023 financial results, revealing a robust balance sheet with over $351 million in cash and equivalents. The company is set to initiate a Phase 2/3 registrational trial of its leading candidate, darovasertib, in combination with crizotinib for patients with HLA-A2 negative metastatic uveal melanoma. Additionally, IDEAYA is expanding its clinical trials for IDE397 and providing updates on multiple ongoing programs. The company anticipates significant clinical updates and milestones in the remainder of 2023.
Read more →IDYA▲ +6%on this news
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
Read more →IDYA▼ -8%on this newsshared move
IDEAYA Announces Pricing of Public Offering IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA ...
IDEAYA Biosciences, Inc. has announced the pricing of an underwritten public offering of common stock and pre-funded warrants, selling 7,439,201 shares at $18.50 each. They are also offering pre-funded warrants to purchase 2,020,270 shares at $18.4999. The total expected gross proceeds from the offering are approximately $175 million, which will be used to support the company's ongoing operations. The offering is expected to close around April 27, 2023, pending customary closing conditions.
Read more →IDYA▲ +35.7%on this newsshared move
IDEAYA Announces Proposed Public Offering of Common Stock
IDEAYA Announces Proposed Public Offering of Common Stock
Read more →IDYA▲ +35.7%on this newsshared move
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First Line Metastatic Uveal Melanoma
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First Line Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
Read more →IDYA▲ +7.2%on this news
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Read more →IDYAIDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First in Class Synthetic Lethality Programs IDE397 MAT2A , IDE161 PARG and Werner Helicase
Read more →IDYA▲ +6.2%on this news
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. reported its financial results for 2022, highlighting a robust balance sheet with approximately $373.1 million in cash and equivalents to support future operations. The company outlined plans for regulatory updates regarding the darovasertib/crizotinib combination therapy for metastatic uveal melanoma, with clinical efficacy data expected mid-2023. Additionally, IDEAYA is advancing its other programs, including IDE161 and IDE397, as part of its commitment to developing innovative oncology therapeutics.
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in March 2023
IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Read more →IDYAIDEAYA Biosciences to Participate in Citis 2023 Virtual Oncology Leadership Summit
IDEAYA Biosciences to Participate in Citis 2023 Virtual Oncology Leadership Summit
Read more →IDYAIDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development ...
IDEAYA Biosciences, Inc. will participate in Citi's 2023 Virtual Oncology Leadership Summit, featuring a fireside chat with CEO Yujiro S. Hata. The event is scheduled for February 21, 2023, and will be accessible through a live audio webcast on IDEAYA's website. A replay of the event will also be available for 30 days post-event. This participation highlights IDEAYA's commitment to advancing its presence in the oncology sector.
Read more →IDYAIDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Read more →IDYA▼ -7.1%on this news
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
IDEAYA Announces IND Clearance by U S FDA enabling Phase 1 Initiation for First in Class PARG Development Candidate IDE161
Read more →IDYAIDEAYA Biosciences to Present at the 41st Annual J P Morgan Healthcare Conference on Tuesday, January 10, 2023
IDEAYA Biosciences to Present at the 41st Annual J P Morgan Healthcare Conference on Tuesday, January 10, 2023
Read more →IDYAIDEAYA Biosciences Appoints Dr Karlene Cimprich, Ph D and Dr Kornelia Polyak, M D , Ph D to Scientific Advisory Board
IDEAYA Biosciences Appoints Dr Karlene Cimprich, Ph D and Dr Kornelia Polyak, M D , Ph D to Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
IDEAYA Biosciences Announces Submission of IND Application to the U S FDA for PARG Development Candidate IDE161
Read more →IDYAIDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R D Day Webcast on Monday, December 12, 2022
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R D Day Webcast on Monday, December 12, 2022
Read more →IDYA▼ -6%on this newsshared move
IDEAYA Biosciences Appoints Darrin M Beaupre, M D , Ph D , as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
IDEAYA Biosciences Appoints Darrin M Beaupre, M D , Ph D , as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of $393.9 million cash, cash equivalents and marketable securities as of September 30, 2022 is anticipated to fund planned operations into 2026 -Reported Ph
Read more →IDYAIDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Upcoming Investor Conferences
IDEAYA Biosciences Announces Plans for Investor R D Day and Participation in Upcoming Investor Conferences
Read more →IDYAIDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First Patient In for Multiple Combination Cohorts in MTAP Deletion Tumors
Read more →IDYA▲ +6.8%on this news
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Read more →IDYAIDEAYA Announces Pricing of Public Offering of Common Stock
IDEAYA Announces Pricing of Public Offering of Common Stock
Read more →IDYA▲ +30.7%on this newsshared move
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
IDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in September 2022
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Read more →IDYAIDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First in Class Pol Theta Helicase Inhibitor Development Candidate
Read more →IDYA▼ -34.8%on this news
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025 -Initiated IDE397
Read more →IDYAIDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors Entered into Clinical Trial Collaboration and Supply Agreement with Amgen to clinica
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors South San Francisco, CA, July 27, 2022 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology compa
Read more →IDYAIDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Read more →IDYAIDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
IDEAYA Announces Development Candidate Nomination of a Potential First in Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Read more →IDYAIDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
Read more →IDYA▲ +12.6%on this news· ran to +26% by day 3
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update • Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update -Strong balance sheet of ~$346 million cash, cash equivalents and marketable securities as of March 31, 2022 is anticipated to fund planned operations into 2025 -Targeting initia
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in May 2022
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
Read more →IDYAIDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
Read more →IDYAIDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Labor
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories South San Francisco, CA, April 6, 2022 IDEAYA Bios
Read more →IDYAIDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$368 million cash, cash equivalents and marketable securities as of
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update South San Francisco, CA, March15, 2022 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of
Read more →IDYAIDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
Read more →IDYAIDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET Driven Tumors
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET Driven Tumors
Read more →IDYAIDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in March 2022
IDEAYA Biosciences to Participate in Investor Conferences in March 2022
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in February 2022
IDEAYA Biosciences to Participate in Investor Conferences in February 2022
Read more →IDYA▲ +6.6%on this newsshared move
IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
IDEAYA Advances First in Class PARG Development Candidate, IDE161, into IND Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
Read more →IDYAIDEAYA Biosciences Announces Corporate and Portfolio Update for J P Morgan 40th Annual Healthcare Conference
IDEAYA Biosciences Announces Corporate and Portfolio Update for J P Morgan 40th Annual Healthcare Conference
Read more →IDYA▼ -9.4%on this news· ran to -23% by day 3shared move
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE TM Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
Read more →IDYA▼ -7.1%on this news· ran to -25% by day 3shared move
IDEAYA Biosciences Appoints Dr Frank McCormick as Chair of Scientific Advisory Board
IDEAYA Biosciences Appoints Dr Frank McCormick as Chair of Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in January 2022
IDEAYA Biosciences to Participate in Investor Conferences in January 2022
Read more →IDYA▲ +7.6%on this news
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in December 2021
IDEAYA Biosciences to Participate in Investor Conferences in December 2021
Read more →IDYA▼ -6.2%on this newsshared move
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned o
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, November 15, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery a
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in November 2021
IDEAYA Biosciences to Participate in Investor Conferences in November 2021
Read more →IDYAIDEAYA Biosciences Appoints Michael White, Ph D , as Chief Scientific Officer
IDEAYA Biosciences Appoints Michael White, Ph D , as Chief Scientific Officer
Read more →IDYAIDEAYA Biosciences to Participate in Investor Conferences in September 2021
IDEAYA Biosciences to Participate in Investor Conferences in September 2021
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - Strong balance sheet of ~$400 million cash, cash equivalents and marketable securities is anticipated to fund planned
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, August 10, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery an
Read more →IDYAIDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021
IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021
Read more →IDYAIDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
Read more →IDYAIDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential bes
IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update South San Francisco, CA, May 10, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de
Read more →IDYAIDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort
IDEAYA Announces Dose Expansion in Phase 1 2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort
Read more →IDYAIDEAYA to Participate in Upcoming May 2021 Investor Relations Event
IDEAYA to Participate in Upcoming May 2021 Investor Relations Event
Read more →IDYAIDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday April 20 2021
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday April 20 2021
Read more →IDYAIDEAYA Reports Darovasertib IDE196 Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
IDEAYA Reports Darovasertib IDE196 Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib IDE196 Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP Deletion Solid Tumors
Read more →IDYAIDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, March 23, 2021 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and
Read more →IDYAIDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
IDEAYA Announces Dose Expansion in Phase 1 2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
Read more →IDYAIDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG and Kinase Inhibitor IDE196
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG and Kinase Inhibitor IDE196
Read more →IDYAIDEAYA to Participate in Upcoming March 2021 Investor Relations Events
IDEAYA to Participate in Upcoming March 2021 Investor Relations Events
Read more →IDYAIDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day
Read more →IDYAIDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors - Dr. Susan L. Kelley was a former clinical development executive in oncology
IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors South San Francisco, CA, February 17, 2021 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine o
Read more →IDYAIDEAYA Announces IDE397 IND Clearance by U S FDA to Initiate Phase 1 and Appointment of Matthew Maurer M D as Vice President Head of Clinical Oncology and Medical Affairs
IDEAYA Announces IDE397 IND Clearance by U S FDA to Initiate Phase 1 and Appointment of Matthew Maurer M D as Vice President Head of Clinical Oncology and Medical Affairs
Read more →IDYAIDEAYA to Participate in Upcoming February 2021 Investor Relations Events
IDEAYA to Participate in Upcoming February 2021 Investor Relations Events
Read more →IDYASpelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
Read more →IDYAIDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U S FDA
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U S FDA
Read more →IDYANASDAQ: IDYA Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences
IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines JPM Healthcare Conference January 2021 Exhibit 99.1 NASDAQ: IDYA Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to
Read more →IDYAIDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
Read more →IDYAIDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences
IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences
Read more →IDYAIDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update - IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, November 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t
Read more →IDYAIDEAYA to Participate in Upcoming November 2020 Investor Relations Events
IDEAYA to Participate in Upcoming November 2020 Investor Relations Events
Read more →IDYAIDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
Read more →IDYAIDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations South San Francisco, CA
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations South San Francisco, CA, September 24, 2020 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncolo
Read more →IDYAIDEAYA to Participate in Upcoming September 2020 Investor Relations Events
IDEAYA to Participate in Upcoming September 2020 Investor Relations Events
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update - Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Hel
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, August 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ta
Read more →IDYAIDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment - Closing of Glaxo Group Equity Investment of $20 Million in IDEAYA at $15.00 per share - Co
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment South San Francisco, CA, August 4, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the disco
Read more →IDYAIDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ 11 Basket Trial
IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ 11 Basket Trial
Read more →IDYAIDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12 2020
IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12 2020
Read more →IDYAIDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib a MEK Inhibitor
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib a MEK Inhibitor
Read more →IDYAIDEAYA Appoints Garret Hampton Ph D to the Board of Directors an Industry Leader in Precision Medicine Oncology and Diagnostics
IDEAYA Appoints Garret Hampton Ph D to the Board of Directors an Industry Leader in Precision Medicine Oncology and Diagnostics
Read more →IDYAExibhit 99.1 IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics - Dr. Garret Hampton serves as President, Clinical Sequencing and Oncology
IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics South San Francisco, CA, June 30, 2020 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the d
Read more →IDYAIDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, an
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology South San Francisco, CA, and London, United Kingdom, June 16, 2020 - IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic pa
Read more →IDYAIDEAYA Biosciences Selected to Join Russell 3000® Index IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted...
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 8, 2020 , ranking them by total market capit
Read more →IDYAIDEAYA Biosciences Selected to Join Russell 3000 R Index
IDEAYA Biosciences Selected to Join Russell 3000 R Index
Read more →IDYAIDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
IDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
Read more →IDYAIDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday June 2 2020
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday June 2 2020
Read more →IDYAIDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
Read more →IDYAIDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update South San Francisco, CA, May 12, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of target
Read more →IDYAIDEAYA Biosciences Announces Addition of Julie Patel as Vice President Human Resources Enhancing its Leadership Team
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President Human Resources Enhancing its Leadership Team
Read more →IDYAIDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, March 24, 2020 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of tar
Read more →IDYAIDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
Read more →IDYAIDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Read more →IDYAIDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities South San Francisco, CA
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities South San Francisco, CA, March 11, 2020 - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused
Read more →IDYAIDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
Read more →IDYACOMPANY LOGO]" Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performan
IDEAYA Biosciences Corporate Presentation JP Morgan Conference January 2020 Exhibit 99.1 "[COMPANY LOGO]" Safe Harbor Statement Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events o
Read more →IDYAIDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted...
Under the agreement, IDEAYA will collaborate with and support research at Boston Children's Hospital in the laboratory of Dr. Joyce Bischoff , Ph.D., Research Associate, Department of Surgery and Professor, Harvard Medical School , who is Principal Investigator of the research st
Read more →IDYAIDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
IDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
Read more →IDYAIDEAYA Biosciences to Present at the 38th Annual J P Morgan Healthcare Conference on Wednesday January 15 2020
IDEAYA Biosciences to Present at the 38th Annual J P Morgan Healthcare Conference on Wednesday January 15 2020
Read more →IDYAExibhit 99.1 IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors South San Francisco, CA
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors South San Francisco, CA, December 18, 2019 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat canc
Read more →IDYAIDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
Read more →IDYAIDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
IDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Read more →IDYAPhase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress - Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT c
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress South San Francisco, CA, November 20, 2019 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted
Read more →IDYAPhase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Phase 1 2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Read more →IDYAIDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update - Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, November 13, 2019 - IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t
Read more →IDYAIDEAYA Biosciences Announces Leadership Updates in Research Organization
IDEAYA Biosciences Announces Leadership Updates in Research Organization
Read more →IDYAIDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
Read more →IDYAIDEAYA Biosciences to Present at Upcoming Investor Conferences
IDEAYA Biosciences to Present at Upcoming Investor Conferences
Read more →IDYAIDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor Agnostic GNAQ 11 Basket Trial
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor Agnostic GNAQ 11 Basket Trial
Read more →IDYAIDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update South San Francisco, CA, August 12, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of tar
Read more →IDYAIDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Read more →IDYAIDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone J D as Chief Financial Officer Andres Ruiz Briseno C P A as Vice President Finance and Mick OQuigley M B A as Vice President Development Operations
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone J D as Chief Financial Officer Andres Ruiz Briseno C P A as Vice President Finance and Mick OQuigley M B A as Vice President Development Operations
Read more →IDYAIDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares South San Francisco, CA
IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares South San Francisco, CA, May 28, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,7
Read more →IDYAIDEAYA Announces Pricing of Initial Public Offering
IDEAYA Announces Pricing of Initial Public Offering
Read more →IDYAIDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
IDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
Read more →IDYAUpdated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Read more →IDYAIDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick Ph D FRS and William Sellers M D to Scientific Advisory Board
IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick Ph D FRS and William Sellers M D to Scientific Advisory Board
Read more →IDYAIDEAYA Biosciences to Present at the 37th Annual J P Morgan Healthcare Conference on Tuesday January 8 2019
IDEAYA Biosciences to Present at the 37th Annual J P Morgan Healthcare Conference on Tuesday January 8 2019
Read more →IDYAIDEAYA Biosciences Inc appoints Bao Truong as Vice President Head of Regulatory Affairs
IDEAYA Biosciences Inc appoints Bao Truong as Vice President Head of Regulatory Affairs
Read more →IDYAIDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1...
SOUTH SAN FRANCISCO, Calif. , Oct. 23, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and
Read more →IDYAIDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
Read more →IDYAIDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
IDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
Read more →IDYAIDEAYA Biosciences Appoints Paul Stone J D as Senior Vice President and General Counsel Head of Operations and Mark Lackner Ph D as Vice President Head of Biomarkers and Synthetic Lethal Biology
IDEAYA Biosciences Appoints Paul Stone J D as Senior Vice President and General Counsel Head of Operations and Mark Lackner Ph D as Vice President Head of Biomarkers and Synthetic Lethal Biology
Read more →IDYAIDEAYA Biosciences Appoints Julie Hambleton M D as Senior Vice President and Chief Medical Officer Head of Development
IDEAYA Biosciences Appoints Julie Hambleton M D as Senior Vice President and Chief Medical Officer Head of Development
Read more →IDYAIDEAYA Biosciences Raises 94 Million Crossover Series B Financing
IDEAYA Biosciences Raises 94 Million Crossover Series B Financing
Read more →IDYAIDEAYA Biosciences Appoints Julie Hambleton, M.D., as Senior Vice President and Chief Medical Officer, Head of Development IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and...
SOUTH SAN FRANCISCO, Calif. , March 13, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the appointment of Julie Hamble
Read more →IDYAIDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG
Read more →IDYAIDEAYA Biosciences to Present at the 36th Annual J P Morgan Healthcare Conference
IDEAYA Biosciences to Present at the 36th Annual J P Morgan Healthcare Conference
Read more →IDYAIDEAYA Biosciences to Participate in Emerging Innovators Panel at Citis 12th Annual Biotech Conference
IDEAYA Biosciences to Participate in Emerging Innovators Panel at Citis 12th Annual Biotech Conference
Read more →IDYAFierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016 IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and...
SAN FRANCISCO and SAN DIEGO , Sept. 19, 2016 /PRNewswire/ -- IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and immune-oncology therapies, today announced that it has been named by Fierce
Read more →IDYAFierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016
FierceBiotech names IDEAYA Biosciences as one of its Fierce 15 Biotech Companies of 2016
Read more →IDYAIDEAYA Biosciences Raises 46 Million Series A and Recruits Leadership and Advisory Board
IDEAYA Biosciences Raises 46 Million Series A and Recruits Leadership and Advisory Board
Read more →Competitive Position
How IDYA ranks across every disease it competes inCompetitive Position is a premium feature
See how IDYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial